FoRx Therapeutics
FoRx Therapeutics is a biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress pathways.
Total raised
€53M
€52,681,527
Funding rounds
2
Investors
4
distinct backers
Active since
2020-04
latest 2025-12
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood32
base rate 44% for Series A
- ▼ Raised very recently
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood16
base rate 12% (2+ rounds)
- ▲ €30M+ raised
- ▲ 7y since founding
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-12-19 | Series A | €43M | EQT Life Sciences,M Ventures,Novartis Venture Fund,Pfizer Ventures | View deal → |
| 2020-04-22 | Seed | €10M | M Ventures | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy